Top

Virology Journal

Published in:

Open Access 01-12-2011 | Research

Design and evaluation of a multi-epitope assembly Peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice

Authors: Xingsheng Wang, Guangyan Xie, Jianming Liao, Dengke Yin, Wenyan Guan, Mingjie Pan, Jingnian Li, Yuexi Li

Published in: Virology Journal | Issue 1/2011

Abstract

Background

Human herpes simplex virus (HSV) 1 and 2 causes oral, ocular, or genital infections, which remains a significant health problem worldwide. HSV-1 and -2 infections in humans range from localized skin infections of the oral, ocular, and genital regions to severe and often disseminated infections in immunocompromised hosts. Epitope based vaccination is a promising mean to achieve protective immunity and to avoid infections with Human herpes simplex virus type 2 (HSV-2).

Methods

The twelve selected epitopes, six B cell epitopes from different glycoprotein of HSV-2 (amino acid residues 466-473 (EQDRKPRN) from envelope glycoprotein B, 216-223 (GRTDRPSA) from C, 6-18 (DPSLKMADPNRFR) from D, 483-491 (DPPERPDSP) from E, 572-579 (EPPDDDDS) from G and 286-295 (CRRRYRRPRG) from I glycoprotein of HSV-2), four CD4⁺ T cell epitopes (amino acid residues 21-28 (NLPVLDQL) from D, 162-177 (KDVTVSQVWFGHRYSQ) from B, 205-224 (KAYQQGVTVDSIGMLPRFIP) from D and 245-259 (KPPYTSTLLPPELSD) from D) and two CD8⁺ T cell epitopes (amino acid residues 10-20 (KMADPNRFRGK) from D and 268-276 (ALLEDPAGT) from D), are responsible for the elicitation of the neutralizing antibodies and cytotoxic T lymphocytes (CTLs) that impart protective immunity to the host. In this study, all above epitopes were inserted into the extracellular fragment (amino acid residues 1-290) of HSV-2 glycoprotein D to construct multi-epitope assembly peptides (MEAPs) by replacing some non-epitope amino acid sequences. The epitope independency of the MEAPs was predicted by three-dimensional software algorithms. The gene of the selected MEAP was expressed in E.coli BL21(DE3), and its protective efficacy against HSV-2 infection was assessed in BALB/c mice.

Results

The MEAP, with each inserted epitopes independently displayed on the molecule surface, was selected as candidate proteins. The results showed that the MEAP was highly immunogenic and could elicit high titer neutralizing antibodies and cell-mediated immune responses.

Conclusions

The MEAP provided complete protection against infection with HSV-2 in mice, which indicates that it might be a potential candidate vaccine against HSV-2.

Available only for authorised users

Corey L: Challenges in genital herpes simplex virus management. J Infect Dis 2002,186(Suppl. 1):S29-S33.CrossRefPubMed

Koelle DM, Corey L: Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol 2003, 16: 96-113. 10.1128/CMR.16.1.96-113.2003CrossRef

Whitley RJ, Roizman B: Herpes simplexvirus infections. Lancet 2001, 35: 1513-1518.CrossRef

Akhtar J, Shukla D: Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J 2009, 276: 7228-36. 10.1111/j.1742-4658.2009.07402.xPubMedCentralCrossRefPubMed

Gianni T, Forghieri C, Campadelli-Fiume G: The herpesvirus glycoproteins B and H/L are sequentially recruited to the receptor bound gD to effect membrane fusion at virus entry. Proc Natl Acad Sci 2006, 103: 14572-7. 10.1073/pnas.0606127103PubMedCentralCrossRefPubMed

Pertel PE, Fridberg A, Parish ML, Spear PG: Cell fusion induced by herpes simplex virus glycoproteins gB, gD, and gH-gL requires a gD receptor but not necessarily heparan sulfate. Virology 2001, 279: 313-32. 10.1006/viro.2000.0713CrossRefPubMed

Krummenacher C, Supekar VM, Whitbeck JC, Lazear E, Connolly SA, Eisenberg RJ, Cohen GH, Wiley DC, Carfi A: Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J 2005, 24: 4144-4153. 10.1038/sj.emboj.7600875PubMedCentralCrossRefPubMed

Pertel PE, Fridberg A, Parish ML: Spear PG Cell fusion induced by herpes simplex virus glycoproteins gB, gD, and gH-gL requires a gD receptor but not necessarily heparan sulfate. Virology 2001, 279: 313-324. 10.1006/viro.2000.0713CrossRefPubMed

Sollne J, Grohmann R, Rapberger R, Perco P, Lukas A, Mayer B: Analysis and prediction of protective continuous B-cell epitopes on pathogen proteins. Immunome Research 2008, 4: 1. 10.1186/1745-7580-4-1CrossRef

10.

Mezo G, Dalmadi B, Mucsi I, Bosze S, Rajnavölgyl E, Hudecz F: Peptide Based Vaccine Design: Synthesis and Immunological Characterization of Branched Polypeptide Conjugates Comprising the 276-284 Immunodominant Epitope of HSV-1 Glycoprotein D. Journal of Peptide Science 2002, 8: 107-117. 10.1002/psc.373CrossRefPubMed

11.

Ghiasi H, Cai S, Perng GC, Nesburn AB, Wechsler SL: Both CD4+ and CD8+ T cells are involved in protection against HSV-1 induced corneal scarring. Br J Ophthalmol 2008, 84: 408-412.CrossRef

12.

Haste AP, Nielsen M, Lund O: Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Science 2006, 15: 2558-2567. 10.1110/ps.062405906CrossRef

13.

Kaur R, Sachdeva G, Vrati S: Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protein. J Infect Dis 2002, 185: 1-12. 10.1086/338015CrossRefPubMed

14.

Cha SC. Kang H, Lee SY, Park GJ, Lee HH: Expression of the HSV-1glycoprotein B gene in insect cells infected by HcNPV recombinant. J Microbiol Biotechnol 2000, 10: 355-362.

15.

Kang H, Cha SC, Han YJ, Park IH, Lee MJ, Byun SM, Lee HH: High level production of glycoprotein protein H of the HSV-1(F) using HcNPV vector system. J Biochem Mol Biol 2000, 33: 483-492.

16.

Geerligs HJ, Clemens H, Kocken M, Drijfhout JW, Weijer WJ, Bloemhoff W, Wilterdink JB, Welling W, Welling-Wester S: Virus neutralizing activity induced by synthetic peptides of glycoprotein D of Herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice. Journal of General virology 1990, 71: 1767-1774. 10.1099/0022-1317-71-8-1767CrossRefPubMed

17.

Cha SC, Kim YS, Cho JK, Cho J, Kim SY, Kang H, Cho MH, Lee HH: Enhanced protection against HSV lethal challenges in mice by immunization with a combined HSV-1 glycoprotein B: H: L gene DNAs. Virus Res 2002, 86: 21-31. 10.1016/S0168-1702(02)00037-0CrossRefPubMed

18.

Khattar S, Collins KPL, Samal SK: Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine 2010, 28: 3159-70. 10.1016/j.vaccine.2010.02.051PubMedCentralCrossRefPubMed

19.

Lee HH, Cha SC, Jang DJ, Lee JK, Choo DW, Kim YS, Uh HS, Kim SY: Immunization with combined HSV-2 glycoproteins B2: D2 gene DNAs: protection against lethal intravaginal challenges in mice. Virus Genes 2002, 25: 179-88. 10.1023/A:1020113902834CrossRefPubMed

20.

Simmons A, Nash AA: Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease. J Virol 1984, 52: 816-21.PubMedCentralPubMed

21.

Saarne T, Kaiser L, Gronlund H, Rasool O, Gafvelin G, Van M: Hage-Hamsten, Rational design of hypoallergens applied to the major cat allergen Fel d 1. Clin Exp Allrgy 2005, 35: 657-663. 10.1111/j.1365-2222.2005.02234.xCrossRef

22.

Sette A, Fikes J: Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 2003, 15: 461-470. 10.1016/S0952-7915(03)00083-9CrossRefPubMed

23.

Groot De AS, McMurry J, Franco J, Rivera D, Kutzler M, Weiner D, Martin B: Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 2005, 23: 2121-2131. 10.1016/j.vaccine.2005.01.059CrossRef

24.

Burgos JS, Serrano-Saiz E, Sastre I, Valdivieso F: ICP47 mediates viral neuroinvasiveness by induction of TAP protein following intravenous inoculation of herpes simplex virus type 1 in mice. J Neurovirol 2006, 12: 420-7. 10.1080/13550280601009546CrossRefPubMed

25.

Wang B, Yao K, Liu G, Xie F, Zhou F, Chen Y: Computational Prediction and Identification of Epstein-Barr Virus Latent Membrane Protein 2A Antigen-Specific CD8⁺T-cell. Cellular & Molecular Immunology 2009, 6: 97-103. 10.1038/cmi.2009.13CrossRef

26.

Kaur R, Vrati S: Development of a recombinant vaccine against Japanese encephalitis. J Neurovirol 2003, 9: 421-431.CrossRefPubMed

27.

Huang YX, Bao YL, Guo SY, Wang Y, Zhou CG, Li YX: Pep-3D-Search: a method for B-cell epitope prediction based on mimotope analysis. BMC Bioinformatics 2008, 9: 5381-5387.

28.

Ponomarenko J, Huynh-Hoa Bui W, Li N, Fusseder P, Bourne E: Alessandro Sette and Bjoern Peters Software EIIiPro: a new structur-based tool for the prediction of antibody epitopes. BMC Bioinformatics 2008, 9: 5141-5148.CrossRef

29.

Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA: Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J Immunol 1994, 152: 549-556.PubMed

30.

Bharati K, Rani R, Vrati S: Evaluation of Japanese encephalitis virus DNA vaccine candidates in rhesus monkeys [ Macaca mulatta ]. Vaccine 2009, 27: 10-16. 10.1016/j.vaccine.2008.10.050CrossRefPubMed

31.

Kimura-Kuroda J, Yasui K: Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodes. J Immunol 1998, 141: 3606-3610.

32.

Murali-Krishna K, Ravi V, Manjunath R: Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitic virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells. J Gen Virol 1996,77(Pt 4):705-714.CrossRefPubMed

Title: Design and evaluation of a multi-epitope assembly Peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice
Authors: Xingsheng Wang
Guangyan Xie
Jianming Liao
Dengke Yin
Wenyan Guan
Mingjie Pan
Jingnian Li
Yuexi Li
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2011
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/1743-422X-8-232

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient

Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells

Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer

Share of afghanistan populace in hepatitis B and hepatitis C infection's pool: is it worthwhile?

Naturally occurring genotype 2b/1a hepatitis C virus in the United States

Development of one-step SYBR Green real-time RT-PCR for quantifying bovine viral diarrhea virus type-1 and its comparison with conventional RT-PCR

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials